Russia’s Pharmstandard To Buy Bever Of Singapore For $590 Million
This article was originally published in PharmAsia News
Executive Summary
Pharmstandard said it plans to buy Bever Pharmaceutical of Singapore for $590 million, giving Russia's largest drug maker control of the key ingredients to its major anti-viral and anti-anxiety over-the-counter brands.